DelveInsight’s ‘Nasal Polyposis (NP)-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Nasal Polyposis (NP), historical and forecasted epidemiology as well as the Nasal Polyposis (NP) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The NP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM NP market size from 2019 to 2032. The Report also covers current NP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019–2032
Nasal Polyposis (NP) Overview
Nasal polyposis (NP) is small, benign (Noncancerous) drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal polyposis tends to be present on both sides of the nasal cavity. Small nasal polyps may not reflect any symptoms, but the larger growths or groups of nasal polyps can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. One-sided nasal polyps may need to be investigated further as they might be malignant nasal or sinus tumors. Nasal polyps are a subgroup of chronic rhinosinusitis (CRS). CRS is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering with CRS condition can be progressed into chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic rhinosinusitis without nasal polyposis (CRSsNP). Only a portion of CRS will develop nasal polyposis.
CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of nasal polyps. People with a history of chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg–Strauss syndrome are more prone to get NP.
Patients suffering from NP may experience Chronic nasal congestion, running nose, Postnasal drip, Reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.
Nasal Polyposis (NP) Diagnosis
For the diagnosis of nasal polyps, an ENT specialist or any other physician first look into nasal passages with a special lighted instrument known as a nasoscope. The most preferred techniques are confirming the location, size, and severity of polyps nasal endoscopy, and radiological imaging. Further allergy tests and blood tests can be done to determine other disease-related components.
Continued in the report…..
Nasal Polyposis (NP) Treatment
The standard treatment for nasal polyposis includes a combination of pharmacological and surgical approaches depending on individual case assessment. In general, patients are treated medically in the primary care setting before considering surgical procedures. Treatment aims to eliminate or significantly reduce the size of the nasal polyps resulting in relief of nasal obstruction, improvement in sinus drainage, restoration of olfaction and taste. Treatment of any accompanying rhinitis symptoms may also be required. With both treatments, recurrences are common, particularly in patients with asthma who are twice as likely to develop recurrence compared with nonasthmatics.
Presently, for the treatment of nasal polyposis corticosteroids (intranasal and systemic) and biologics (Dupixent, Xolair, and Nucala) can be used. Corticosteroid implants such as Propel and Sinuva are also available to improve the outcomes of surgery and to be used in recurrent nasal polyposis, respectively. In addition anti-histamines, antibiotics, and NSAIDs can be given depending on the patient's need. If the patient does not show improvement by therapeutics agents then surgery can be also performed to remove the polyps.
Some biologics are also preferred treatment options in the NP patient group. Interleukins 4 and 13 may aggravate nasal polyps, and inhibition with dupilumab (Dupixent) has been shown to decrease polyp burden and improve symptoms.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of chronic rhinosinusitis (CRS), diagnosed prevalent cases of chronic rhinosinusitis (CRS), diagnosed prevalent cases of nasal polyposis and gender-specific diagnosed prevalent cases of nasal polyposis scenario of Nasal Polyposis (NP) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Key Findings
The epidemiology segment also provides the Nasal Polyposis (NP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the Nasal Polyposis (NP) report encloses the detailed analysis of Nasal Polyposis (NP) marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Nasal Polyposis (NP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.
Nasal Polyposis (NP) Marketed Drugs
Nucala (Mepolizumab): GlaxoSmithKline
GSK’s Nucala (Mepolizumab) is the first IL-5 therapy approved as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps to target eosinophilic inflammation in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. Nucala got recently approved by US FDA based on positive results from the pivotal Synapse study.
Products detail in the report…
Dupixent (Dupilumab): Sanofi/Regeneron Pharmaceuticals
Dupixent is an interleukin-4 receptor alpha antagonist, indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). Patients with comorbid CRSwNP and asthma are often more difficult to treat, so it is encouraging that Dupixent, which targets key drivers of Type 2 inflammation, may address both conditions in these patients.
Products detail in the report…
Xolair (Omalizumab): Hoffmann-La Roche/Novartis
Xolair (omalizumab) is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation. Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is administered as a subcutaneous (SC) injection and is available in prefilled syringes and vials. Injection form is a lyophilized, white, sterile powder in a 150 mg single-dose vial without preservatives, and prefilled Syringe is available in 75 mg and 150 mg
Products detail in the report…
Nasal Polyposis (NP) Emerging Drugs
Fasenra (benralizumab): AstraZeneca
Fasenra (benralizumab), being developed by AstraZeneca, is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). Fasenra targets seven diseases beyond respiratory disease. In 2021, the company filed the NDA application in the US and planning to file the dossier in Europe and Japan in 2022.
Products detail in the report…
Tezepelumab: AstraZeneca/Amgen
AstraZeneca in collaboration with Amgen is developing Tezepelumab as a potential human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). TSLP is an epithelial-derived cytokine produced in response to airborne stimuli, such as allergens, viruses, and diesel exhaust. It plays a key role in the initiation and persistence of airway inflammation by activating multiple downstream inflammatory pathways. TSLP expression is elevated in the airways of patients with asthma compared with healthy individuals and in nasal polyp tissue from patients with CRSwNP compared with healthy sinus tissue or that from patients with CRS without NP. Tezepelumab is in Phase III clinical trial for nasal polyps and other indications. The positive response for CRSwNP Tezepelumab was explored from the clinical trials; specifically, Pathway and Navigator, dedicated for the Asthma indication.
Products detail in the report…
CBP-201: Connect Biopharma
CBP-201, discovered internally using Connect Biopharma’s proprietary Immune Modulation Technology Platform, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα). CBP-201 is being investigated for CRSwNP, Atopic dermatitis (AD), and Type 2 inflammation with a focus to show rapid onset and sustained improvements in clinical outcomes with a convenient dosing frequency. The ongoing Phase IIb global clinical trial in CRSwNP is supposed to support the clinical outcomes of atopic dermatitis and asthma.
Products detail in the report…
List to be continued in the report…
Regardless of the discovery of biomarkers, the current treatment paradigm revolves around non-biomarker-specific treatment choices. Symptomatic nasal polyposis patients are initially started with intranasal steroids, and the subsequent options remain a short course of oral corticosteroids and then surgical intervention. Recently the market of nasal polyposis welcomed three biologics (Nucala: mepolizumab; Dupixent: dupilumab; Xolair: omalizumab). Experts say biologics are considered before primary surgery, particularly in patients whom conditions like asthma are present simultaneously with CRSwNP, in those for whom surgery is less available, in patients who refuse surgery, and/or patients with a high complication ratio. The use of biologics straightaway after surgery might be considered for patients whose nasal polyps recur a year after the surgery.
For many patients with uncontrolled or severe disease, a combination of sinus surgery and the use of a biologic that is targeted to their precise endotype may be the optimal treatment strategy. However, which surgical approach and which biologics are best for each patient are debates that remain ongoing.
According to DelveInsight, Nasal Polyposis (NP) 7MM is expected to change in the study period 2019–2032.
Key Findings
The United States Market Outlook
This section provides the total Nasal Polyposis (NP) market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Nasal Polyposis (NP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Nasal Polyposis (NP) market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs recently launched in the Nasal Polyposis (NP) market or expected to get launched in the market during the study period 2019–2032. The analysis covers Nasal Polyposis (NP) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Nasal Polyposis (NP) emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive and market Intelligence analysis of the Nasal Polyposis (NP) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
1. Key Insights
2. Report Introduction
3. Nasal Polyposis Market Overview at a Glance
3.1. Market Share (%) Distribution of Nasal Polyposis by Therapies in 2019
3.2. Market Share (%) Distribution of Nasal Polyposis by Therapies in 2032
4. Nasal Polyposis Market: Future Perspective
5. Executive Summary of Nasal Polyposis
6. Key Events
7. Disease Background and Overview: Nasal Polyposis
7.1. Introduction
7.2. Signs and Symptoms
7.3. Etiology
7.4. Causes
7.5. Pathogenesis
7.6. Diagnostic Approach
7.6.1. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis
7.6.2. Diagnostic Algorithm
7.7. Treatment and Management
7.7.1. Treatment Algorithm
7.7.2. Treatment Recommendations
7.7.2.1. European forum for research and education in allergy and airway diseases
7.7.2.2. International Consensus Statement on Rhinology and Allergy
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
8.3.1. United States
8.3.2. Five Major European Countries (Germany, France, Italy, Spain and the United Kingdom)
8.3.3. Japan
8.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM
8.5. Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM
8.6. The United States
8.6.1. Prevalent Cases of Chronic Rhinosinusitis in the United States
8.6.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the United States
8.6.3. Diagnosed Prevalent Cases of Nasal Polyposis in the United States
8.6.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the United States
8.7. Major Five European Countries
8.7.1. Prevalent Cases of Chronic Rhinosinusitis in the EU-5
8.7.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5
8.7.3. Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5
8.7.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5
8.8. Japan
8.8.1. Prevalent Cases of Chronic Rhinosinusitis in Japan
8.8.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan
8.8.3. Diagnosed Prevalent Cases of Nasal Polyposis in Japan
8.8.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan
9. Patient Journey
10. Marketed Therapies
10.1. Nucala (Mepolizumab): GlaxoSmithKline
10.1.1. Product Description
10.1.2. Regulatory Milestones
10.1.3. Other Developmental activities
10.1.4. Clinical Development
10.1.5. Clinical Trials Information
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.1.8. Analysts’ Views
10.2. Xhance (Fluticasone Propionate): Optinose US Inc.
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental activities
10.2.4. Clinical Development
10.2.5. Clinical Trials Information
10.2.6. Safety and Efficacy
10.2.7. Product Profile
10.3. Dupixent (Dupilumab): Sanofi/Regeneron Pharmaceuticals
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental activities
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and Efficacy
10.3.7. Product Profile
10.3.8. Analysts’ Views
10.4. Xolair (Omalizumab): Hoffmann-La Roche/Novartis
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Other Developmental activities
10.4.4. Clinical Development
10.4.5. Clinical Trials Information
10.4.6. Safety and Efficacy
10.4.7. Product Profile
10.4.8. Analysts’ Views
10.5. Sinuva (Mometasone Furoate) Sinus Implant: Intersect ENT
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Clinical Development
10.5.4. Clinical Trials Information
10.5.5. Safety and Efficacy
10.5.6. Product Profile
10.6. Propel (Mometasone Furoate): Intersect ENT
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Other Developmental activities
10.6.4. Clinical Development
10.6.5. Clinical Trials Information
10.6.6. Safety and Efficacy
10.6.7. Product Profile
11. Emerging Drugs
11.1. Key Cross Competition
11.2. Fasenra (benralizumab): AstraZeneca
11.2.1. Product Description
11.2.2. Development activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.2.7. Analysts’ Views
11.3. Tezepelumab: AstraZeneca/Amgen
11.3.1. Product Description
11.3.2. Development activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.3.7. Analysts’ Views
11.4. CBP-201: Connect Biopharma
11.4.1. Product Description
11.4.2. Clinical Development
11.4.3. Clinical Trials Information
11.4.4. Product Profile
11.4.5. Analysts’ Views
12. Nasal Polyposis: Seven Major Market Analysis
12.1. Key Findings
12.2. Methodology of Nasal Polyposis Market
12.3. Market Size of Nasal Polyposis in the 7MM
12.4. Market Size of Nasal Polyposis by Therapies in the 7MM
12.5. Potential of Emerging Biologics in the Nasal Polyposis Treatment Market
12.6. Key Market Forecast Assumptions
12.7. Attribute Analysis
12.8. Market Outlook
12.9. Market Size of Nasal Polyposis in the United States
12.9.1. Total Market Size of Nasal Polyposis
12.9.2. Market Size of Nasal Polyposis by Therapies
12.10. Market Size of Nasal Polyposis in the Major Five European Countries
12.10.1. Total Market Size of Nasal Polyposis
12.10.2. Market Size of Nasal Polyposis by Therapies
12.11. Market Size of Nasal Polyposis in Japan
12.11.1. Total Market Size of Nasal Polyposis
12.11.2. Market Size of Nasal Polyposis by Therapies
13. KOL Views
13.1. United States
13.2. EU-5
13.3. Japan
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Reimbursement and Market Access
19. Appendix
19.1. Bibliography
19.2. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
List of Table
Table 1: Summary of Nasal Polyposis Market and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis
Table 4: Grade A/B evidence-based recommendations for medical management of Chronic Rhinosinusitis with Nasal Polyposis (1)
Table 5: Grade A/B evidence-based recommendations for medical management of Chronic Rhinosinusitis with Nasal Polyposis (2)
Table 6: Grade A/B evidence-based recommendations for medical management of Chronic Rhinosinusitis with Nasal Polyposis (3)
Table 7: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM (2019–2032)
Table 8: Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM (2019–2032)
Table 9: Prevalent Cases of Chronic Rhinosinusitis in the United States (2019–2032)
Table 10: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the US (2019–2032)
Table 11: Diagnosed Prevalent Cases of Nasal Polyposis in the US (2019–2032)
Table 12: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the US (2019–2032)
Table 13: Prevalent Cases of Chronic Rhinosinusitis in the EU-5 (2019–2032)
Table 14: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5 (2019–2032)
Table 15: Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5 (2019–2032)
Table 16: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5 (2019–2032)
Table 17: Prevalent Cases of Chronic Rhinosinusitis in Japan (2019–2032)
Table 18: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan (2019–2032)
Table 19: Diagnosed Prevalent Cases of Nasal Polyposis in Japan (2019–2032)
Table 20: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan (2019–2032)
Table 21: Nucala, Clinical Trial Description, 2022
Table 22: Xhance, Clinical Trial Description, 2022
Table 23: Dupixent, Clinical Trial Description, 2022
Table 24: Xolair, Clinical Trial Description, 2022
Table 25: Sinuva, Clinical Trial Description, 2022
Table 26: Propel, Clinical Trial Description, 2022
Table 27: Comparison of emerging drugs under development
Table 28: Fasenra, Clinical Trial Description, 2022
Table 29: Tezepelumab, Clinical Trial Description, 2022
Table 30: CBP-201, Clinical Trial Description, 2022
Table 31: Market Size of Nasal Polyposis in the 7MM in USD million (2019–2032)
Table 32: Market Size of Nasal Polyposis by Therapies in the 7MM in USD million (2019–2032)
Table 33: Key Market Forecast Assumptions for Nucala (Mepolizumab)
Table 34: Key Market Forecast Assumptions for Fasenra (benralizumab)
Table 35: Key Market Forecast Assumptions for Tezepelumab
Table 36: Key Market Forecast Assumptions for CBP-201
Table 37: United States Market Size of Nasal Polyposis in USD Million (2019–2032)
Table 38: Market Size of Nasal Polyposis by Therapies in the US in USD million (2019–2032)
Table 39: EU-5 Market Size of Nasal Polyposis in USD Million (2019–2032)
Table 40: Market Size of Nasal Polyposis by Therapies in Germany in USD million (2019–2032)
Table 41: Market Size of Nasal Polyposis by Therapies in France in USD million (2019–2032)
Table 42: Market Size of Nasal Polyposis by Therapies in Italy in USD million (2019–2032)
Table 43: Market Size of Nasal Polyposis by Therapies in Spain in USD million (2019–2032)
Table 44: Market Size of Nasal Polyposis by Therapies in the UK in USD million (2019–2032)
Table 45: Market Size of Nasal Polyposis by Therapies in the EU-5 in USD million (2019–2032)
Table 46: Market Size of Nasal Polyposis in Japan, in USD Million (2019–2032)
Table 47: Market Size of Nasal Polyposis by Therapies in Japan in USD million (2019–2032)
List of Figures
Figure 1: Nasal polyps in the nose and sinus cavity
Figure 2: Anatomy of normal nasal area vs. Chronic Rhinosinusitis with Nasal Polyposis
Figure 3: Radiographic findings in severe Chronic Rhinosinusitis with Nasal Polyposis
Figure 4: Primary symptoms of Nasal polyps
Figure 5: Secondary symptoms of Nasal polyps
Figure 6: Etiology of Nasal Polyps
Figure 7: Causes of Nasal Polyps
Figure 8: Hypothetical timeline and interactions of events in the formation of nasal polyps
Figure 9: Differential diagnosis of nasal polyps
Figure 10: Diagnostic algorithm of refractory chronic rhinosinusitis
Figure 11: Four-step diagnosis of sinonasal disorders
Figure 12: Diagnostic-therapeutic Algorithm in Nasal Polyposis
Figure 13: Treatment algorithm for chronic rhinosinusitis with nasal polyps
Figure 14: Prognostic index of nasal polyp relapse based on clinical and cytologic grading
Figure 15: Flow chart of nasal polyp treatment based on the proposed grading
Figure 16: Management of uncontrolled severe Chronic Rhinosinusitis with Nasal Polyposis as per EUFOREA experts
Figure 17: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM (2019–2032)
Figure 18: Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM (2019–2032)
Figure 19: Prevalent Cases of Chronic Rhinosinusitis in the United States (2019–2032)
Figure 20: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the US (2019–2032)
Figure 21: Diagnosed Prevalent Cases of Nasal Polyposis in the US (2019–2032)
Figure 22: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the US (2019–2032)
Figure 23: Prevalent Cases of Chronic Rhinosinusitis in the EU-5 (2019–2032)
Figure 24: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5 (2019–2032)
Figure 25: Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5 (2019–2032)
Figure 26: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5 (2019–2032)
Figure 27: Prevalent Cases of Chronic Rhinosinusitis in Japan (2019–2032)
Figure 28: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan (2019–2032)
Figure 29: Diagnosed Prevalent Cases of Nasal Polyposis in Japan (2019–2032)
Figure 30: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan (2019–2032)
Figure 31: Patient Journey
Figure 32: Market Size of Nasal Polyposis in the 7MM in USD million (2019–2032)
Figure 33: Market Size of Nasal Polyposis by Therapies in the 7MM in USD million (2019–2032)
Figure 34: Market Size of Nasal Polyposis in the United States, USD Millions (2019–2032)
Figure 35: Market Size of Nasal Polyposis by Therapies in the United States, in USD Million (2019–2032)
Figure 36: Market Size of Nasal Polyposis in the EU-5, USD Millions (2019–2032)
Figure 37: Market Size of Nasal Polyposis by Therapies, in the EU-5, in USD Million (2019–2032)
Figure 38: Market Size of Nasal Polyposis in Japan, USD Millions (2019–2032)
Figure 39: Market Size of Nasal Polyposis by Therapies in Japan, in USD Million (2019–2032)
Figure 40: Market Drivers
Figure 41: Market Barriers
Figure 42: SWOT Analysis
Figure 43: Unmet Needs
GlaxoSmithKline
Optinose US Inc.
Sanofi
Regeneron Pharmaceuticals
Hoffmann-La Roche
Novartis
Intersect ENT
AstraZeneca
AstraZeneca
Amgen
Connect Biopharma
